select trial semaglutide nejm — Blog — NephJC Semaglutide and Cardiovascular Outcomes in

W.WagemakersL.SchoutenA.van KanJ

Effects of lixisenatide versus liraglutide (short- and long-acting GLP-1 receptor agonists) on esophageal and gastric function in patients with type 2 diabetes

A realistic and sustainable rate of progress is 510 lbs per month

It does not undo cortisol dysregulation from chronic stress

Regarding newer agents, evidence from phase 2 trials indicates that the triple agonist retatrutide (GLP-1R/GIPR/GCGR) can achieve unprecedented weight loss of up to 24.4% (Jastreboff et al., 2023)

To mitigate risks, interdisciplinary collaboration among pharmacists, physicians, and nutrition specialists is essential to systematically identify and manage medication-nutrient interactions (96)